Pfizer
PFE
2,922 hedge funds and large institutions have $92.9B invested in Pfizer in 2025 Q4 according to their latest regulatory filings, with 334 funds opening new positions, 1,078 increasing their positions, 1,270 reducing their positions, and 172 closing their positions.
94% more first-time investments, than exits
New positions opened: 334 | Existing positions closed: 172
4% more funds holding
Funds holding: 2,819 → 2,922 (+103)
1.74% more ownership
Funds ownership: 63.85% → 65.59% (+1.7%)
0% more capital invested
Capital invested by funds: $92.5B → $92.9B (+$411M)
11% less funds holding in top 10
Funds holding in top 10: 35 → 31 (-4)
15% less repeat investments, than reductions
Existing positions increased: 1,078 | Existing positions reduced: 1,270
19% less call options, than puts
Call options by funds: $2.6B | Put options by funds: $3.2B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$362M |
| 2 |
Bank of New York Mellon
New York
|
+$342M |
| 3 |
Janus Henderson Group
London,
|
+$189M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$184M |
| 5 |
Goldman Sachs
New York
|
+$183M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$450M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$223M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$211M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$167M |
| 5 |
Jane Street
New York
|
-$146M |
PFE Hedge Fund Activity: Q4 2025 in Review
2,922 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2025, worth a combined $92.9B — up 0.44% from $92.5B a quarter earlier.
Buyers outnumbered sellers: 334 funds opened new PFE positions and 172 closed out — a net gain of 162 holders — while 1,078 added to existing stakes and 1,270 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $362M. The largest seller was Arrowstreet Capital, cutting an estimated $450M.
- 2,922 institutional investors held Pfizer (PFE) as of Q4 2025, up from 2,819 in Q3 2025.
- Funds reported $92.9B of Pfizer stock for Q4 2025, up 0.44% quarter-over-quarter.
- 334 funds opened new Pfizer positions in Q4 2025 and 172 closed out, a net change of +162 holders.
- The largest Pfizer buyer in Q4 2025 was Morgan Stanley, an estimated $362M added.
- The largest Pfizer seller in Q4 2025 was Arrowstreet Capital, an estimated $450M sold.
Based on aggregated 13F filings for Q4 2025.